GW Pharmaceuticals Plc (GWPH) financial statements (2023 and earlier)

Company profile

Business Address SOVEREIGN HOUSE
HISTON, CAMBRIDGE CB24 9BZ, 00000
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
9/30/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 537355
Cash and cash equivalents 537355
Receivables 492
Inventory, net of allowances, customer advances and progress billings 8619
Inventory 8619
Other undisclosed current assets 2815
Total current assets: 700391
Noncurrent Assets
Finance lease, right-of-use asset 6
Operating lease, right-of-use asset 25
Property, plant and equipment 12882
Intangible assets, net (including goodwill) 77
Goodwill 77
Other noncurrent assets 53
Deferred tax assets, net7
Other undisclosed noncurrent assets 13 
Total noncurrent assets: 183100
TOTAL ASSETS: 882491
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 11058
Accounts payable 1010
Accrued liabilities 9947
Taxes payable 01
Other liabilities 81
Total current liabilities: 11859
Noncurrent Liabilities
Long-term debt and lease obligation 272
Finance lease, liability 6
Capital lease obligations2
Operating lease, liability 22
Liabilities, other than long-term debt 1111
Other liabilities 1111
Other undisclosed noncurrent liabilities  4
Total noncurrent liabilities: 3917
Total liabilities: 15675
Stockholders' equity
Stockholders' equity attributable to parent 726415
Common stock 11
Additional paid in capital 1,6321,247
Accumulated other comprehensive loss (69)(75)
Accumulated deficit (838)(757)
Total stockholders' equity: 726415
TOTAL LIABILITIES AND EQUITY: 882491

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
9/30/2018
Revenues 31113
Cost of revenue (131)(6)
Cost of goods and services sold (27)(6)
Gross profit: 1807
Operating expenses (299)(296)
Operating loss: (118)(289)
Nonoperating income (expense) 110(1)
Investment income, nonoperating 84
Foreign currency transaction loss, before tax (2)(5)
Other nonoperating income 104 
Interest and debt expense (1)(1)
Loss from continuing operations before income taxes: (9)(291)
Income tax expense (benefit) 0(4)
Net loss available to common stockholders, diluted: (9)(295)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
9/30/2018
Net loss: (9)(295)
Comprehensive loss: (9)(295)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 10(1)
Comprehensive income (loss), net of tax, attributable to parent: 1(296)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: